Cargando…
Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression
CLN2 neuronal ceroid lipofuscinosis is a hereditary lysosomal storage disease with primarily neurological signs that results from mutations in TPP1, which encodes the lysosomal enzyme tripeptidyl peptidase-1 (TPP1). Studies using a canine model for this disorder demonstrated that delivery of TPP1 en...
Autores principales: | Katz, M L, Johnson, G C, Leach, S B, Williamson, B G, Coates, J R, Whiting, R E H, Vansteenkiste, D P, Whitney, M S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398942/ https://www.ncbi.nlm.nih.gov/pubmed/28079862 http://dx.doi.org/10.1038/gt.2017.4 |
Ejemplares similares
-
Characterization of neurological disease progression in a canine model of CLN5 neuronal ceroid lipofuscinosis
por: Meiman, Elizabeth J., et al.
Publicado: (2022) -
A Missense Mutation in Canine CLN6 in an Australian Shepherd with Neuronal Ceroid Lipofuscinosis
por: Katz, Martin L., et al.
Publicado: (2011) -
Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)
por: Katz, Martin L, et al.
Publicado: (2014) -
in vivo localization of the neuronal ceroid lipofuscinosis proteins, CLN3 and CLN7, at endogenous expression levels
por: Mohammed, Alamin, et al.
Publicado: (2017) -
Novel CLN1 mutation with atypical juvenile neuronal ceroid lipofuscinosis
por: Khan, Arif, et al.
Publicado: (2013)